Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 338.00
Bid: 337.00
Ask: 343.00
Change: 0.00 (0.00%)
Spread: 6.00 (1.78%)
Open: 338.00
High: 0.00
Low: 0.00
Prev. Close: 338.00
APTD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

7 Jul 2009 07:00

RNS Number : 2015V
Microgen PLC
07 July 2009
 



microgen

www.microgen.com

 7 July 2009

M icrogen plc

Trading Update

Microgen plc ('Microgen' or 'the Group'provides an update on trading ahead of the Group's Interim Results, for the six months ended 30 June 2009, which are anticipated to be released in late July. 

During the first half of 2009, Microgen Aptitude Solutions Division ("MASD") has seen considerable success. In addition to the multi-million pound contract reported in the April Interim Management Statementthe division is also now engaged on three significant new customer projects :

Major UK Bank : MASD has recently signed a contract for Microgen Accounting Hub and Microgen Aptitude. This project is anticipated to produce revenue in excess of £1 million in the coming year.

US Manufacturer : In parallel with final contract negotiations, MASD is commencing the initial design phase of a project for Microgen Aptitude which is also anticipated to produce revenue in excess of £1 million in the coming year.

Major US Financial Institution : MASD is currently undertaking a significant customer-funded proof-of-concept which may or may not lead to a major contract for Microgen Aptitude and/or Microgen Accounting Hub.

As a result of these projects and additional prospects, the Board anticipates MASD delivering a strong second half of the year. The operating loss for MASD in the first-half has significantly reduced compared to the prior year. Microgen expenses all development costs as incurred and has no R&D capitalisation on its balance sheet. This results in a high correlation between operating income and cash flow for the Group as a whole and, as the revenue increases within MASD, profitability of this division should scale accordingly.

As anticipated, the Group's Billing Services Division and Financial Systems Division have reflected the economic climate but are trading in line with the Board's expectations. These divisions have high recurring revenue and hence remain profitable, high margin businesses with strong cash flow.

Cash at 30 June 2009 was £15.2 million, compared to £14.7 million at 31 December 2008, after repayment of £1.3 million of the loan associated with the freehold property and payment of the final dividend of £1.2 million.

Overall, despite the continuing difficult market environment, the first half of 2009 is anticipated to be in line with the Board's expectations, but, as a result of the strong MASD performance, and subject to contracts being finalised for the two projects noted aboveearnings for the year are anticipated to be ahead of current market expectations.

Contacts

Martyn Ratcliffe, Chairman

01252-772300

David Sherriff, Chief Operating Officer

Philip Wood, Group Finance Director

Giles Sanderson, Financial Dynamics

Haya Chelhot, Financial Dynamics

020-7831-3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBSGDRXXGGGCL
Date   Source Headline
20th May 20244:38 pmRNSNotification of Major Holdings
20th May 20247:00 amRNSTransaction in Own Shares
17th May 20247:00 amRNSTransaction in Own Shares
15th May 20247:00 amRNSTransaction in Own Shares
14th May 202410:48 amRNSResult of AGM
14th May 20247:00 amRNSAGM Statement
10th May 20247:00 amRNSTransaction in Own Shares
8th May 20247:00 amRNSNotification of Major Holdings
8th May 20247:00 amRNSTransaction in Own Shares
7th May 20247:00 amRNSTransaction in Own Shares
3rd May 20247:00 amRNSTransaction in Own Shares
1st May 20244:10 pmRNSTotal Voting Rights
30th Apr 20244:46 pmRNSGrant of awards under 2020 Deferred Bonus Plan
29th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSNotice of 2024 Annual General Meeting
8th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20241:46 pmRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:01 amRNSAptitude to Accelerate Autonomous Finance
21st Mar 20247:01 amRNSShare buyback programme
21st Mar 20247:00 amRNSAudited Results for Year Ended 31 December 2023
21st Feb 20247:00 amRNSChange of Broker Arrangements
9th Feb 20247:00 amRNSHolding(s) in Company
31st Jan 20247:00 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSFull Year Trading Update and Notice of Results
4th Jan 20247:00 amRNSFynapse Win
30th Nov 20237:00 amRNSAppointment of Chief Executive Officer
12th Oct 20237:00 amRNSHolding(s) in Company
2nd Oct 20232:17 pmRNSGrant of awards
29th Sep 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
21st Sep 20232:28 pmRNSHolding(s) in Company
20th Sep 20239:32 amRNSHolding(s) in Company
7th Sep 202310:15 amRNSGrant of Awards under Performance Share Plan
23rd Aug 20231:21 pmRNSHolding(s) in Company
23rd Aug 20231:15 pmRNSHolding(s) in Company
28th Jul 202312:18 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.